These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12930561)

  • 1. Interim analyses of data as they accumulate in laboratory experimentation.
    Ludbrook J
    BMC Med Res Methodol; 2003 Aug; 3():15. PubMed ID: 12930561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An introduction to the use of interim data analyses in clinical trials.
    Lewis RJ
    Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of state of the art statistical methodology in biomedical research: the example of methodology for interim analyses in clinical trials].
    Muñoz SR; Bangdiwala SI
    Rev Med Chil; 2001 Sep; 129(9):983-8. PubMed ID: 11725478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive group sequential test with changing patient population.
    Feng H; Liu Q
    J Biopharm Stat; 2012; 22(4):662-78. PubMed ID: 22651107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interim analysis in therapeutic trials: a brief survey of current developments].
    Falissard B; Lellouch J
    Rev Epidemiol Sante Publique; 1991; 39(4):365-72. PubMed ID: 1754702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much do we have to pay for how many interim analyses?
    Koch A
    Contemp Clin Trials; 2005 Feb; 26(1):113-6. PubMed ID: 15837456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive group sequential test for clinical trials with changing patient population.
    Feng H; Shao J; Chow SC
    J Biopharm Stat; 2007; 17(6):1227-38. PubMed ID: 18027228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting and reporting clinical trials with results of borderline significance.
    Hackshaw A; Kirkwood A
    BMJ; 2011 Jul; 343():d3340. PubMed ID: 21727163
    [No Abstract]   [Full Text] [Related]  

  • 19. [Justification of repeated animal experiments and determination of the required number of animals according to the German Animal Protection Act].
    Schneider B
    Arzneimittelforschung; 2009; 59(6):318-25. PubMed ID: 19634514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated confidence intervals for adaptive group sequential trials.
    Mehta CR; Bauer P; Posch M; Brannath W
    Stat Med; 2007 Dec; 26(30):5422-33. PubMed ID: 17918195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.